Nuvisertib

Nuvisertib is an orally available, second-generation and selective ATP-competitive inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, nuvisertib selectively binds to and prevents the activation of the PIM kinases. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIM. PIMs, constitutively active proto-oncogenic serine/threonine kinases, are upregulated in various types of cancers and play key roles in tumor cell proliferation and survival. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include 2-(trans-4-((3-(3-(Trifluoromethyl)phenyl)imidazo[1, 2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol, 2-((1r, 4r)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1 and 2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol. Its PubChem CID is 66598080.

CAS No 1361951-15-6
Molecular Formula C22H25F3N4O
Molecular Weight 418.5 g/mol
Synonyms 2-[4-[[3-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexyl]propan-2-ol

Frequently Asked Questions